Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Tufts Medical Center
Modality
protein_peptide
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05700864CT.gov NGF Treatment for Patients With Neuropathic Corneal Pain | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Corneal Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cenegermin-Bkbj (this asset) | Tufts Medical Center | P1 | CC · 43 |
| Pomalidomide | Hellenic Society of Hematology | P1/2 | CC |
| Lenalidomide | Hellenic Society of Hematology | P1/2 | CC |
| Belantamab Mafodotin | Hellenic Society of Hematology | P1/2 | CC |
| Dexasone | Hellenic Society of Hematology | P1/2 | CC |
| Daratumumab | Hellenic Society of Hematology | P1/2 | CC |
| Nirogacestat | Hellenic Society of Hematology | P1/2 | CC |
| Human Cord Blood Plasma | Singapore Eye Research Institute | N/A | D |
Other indications for Cenegermin-Bkbj
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral Neuropathy | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cenegermin-Bkbj in Corneal Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cenegermin-bkbj-corneal-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →